Blood Clues Expose Fake Heart Attacks

Doctors now have a blood test that can tell a heart attack from “broken heart syndrome” before a patient ever reaches the catheterization lab.

Quick Take

Researchers built a biomarker score called BioTAK to tell Takotsubo syndrome apart from a real heart attack.
The score was tested on 1,823 patients, then checked again on 1,792 more patients in a separate group.
It correctly sorted almost 90% of patients into a likely diagnosis before invasive testing began.
The tool adds to, rather than replaces, existing methods like the InterTAK score and coronary angiography.

A Heart Condition That Mimics a Heart Attack

Takotsubo syndrome, often called broken heart syndrome, hits the heart hard enough to fool even trained physicians. It causes chest pain, abnormal heart rhythms on an electrocardiogram, and elevated blood markers just like a true heart attack. For years, the only reliable way to tell the two apart was to send patients into the catheterization lab and look directly at the coronary arteries.

The Score That Reads the Blood Before the Catheter Goes In

A team working with researchers from the universities of Zurich and Greifswald built BioTAK using five biomarkers tied to heart stress, blood vessel tightening, anxiety regulation, and fat metabolism. Published in the European Heart Journal, the score was developed on 1,823 patients, including 69 confirmed Takotsubo cases, then tested again on 1,792 independent patients with 77 confirmed cases.

The results were strong. In the first group, the score separated Takotsubo from acute coronary syndrome with a near-perfect accuracy rating. In the second, independent group, it still performed at a high level, with researchers reporting good calibration between predicted and actual outcomes.

Doctors set two cutoff points on the score. Patients below the low-risk threshold had a 98.6% sensitivity rate and a negative predictive value of 99.9%, meaning a low score almost always ruled out Takotsubo syndrome correctly. Using both cutoffs together, the score sorted almost 90% of patients into a likely diagnosis before anyone performed invasive coronary angiography.

Why Skipping the Cath Lab Sooner Matters

Coronary angiography is not a simple errand. It means threading a catheter through an artery, exposing patients to radiation and contrast dye, and tying up a hospital’s cardiac team. News coverage of the study highlighted that predefined thresholds let doctors correctly classify nearly nine out of ten patients before that invasive step even happened. For a health system stretched thin, faster and cheaper sorting at the front door has real value.

Takotsubo syndrome has long been treated as a diagnosis of exclusion, confirmed only after ruling everything else out in the cath lab. That approach works, but it costs time, money, and puts patients through an invasive procedure that a blood test might one day make unnecessary in many cases. BioTAK does not claim to end angiography. It claims to help doctors decide who truly needs it first.

An Existing Tool Gets New Competition

BioTAK is not the first attempt to solve this puzzle. The InterTAK Diagnostic Score, built from clinical and electrocardiogram data rather than blood biomarkers, has already shown strong results in differentiating the two conditions, with one validation study reporting a sensitivity of 89% and specificity of 91%. BioTAK adds a lab-based option to that existing framework rather than entering an empty field, giving physicians another layer of evidence to weigh alongside clinical judgment.

The next real test for BioTAK is not in a spreadsheet but in the emergency room. Whether the score actually cuts down unnecessary catheterizations, speeds up correct diagnoses, and holds up across different hospitals and labs will depend on further studies now that the initial validation is public. For patients rushed in with chest pain, that next round of research could decide how soon a five-marker blood panel starts standing in for a catheter.